IDH-mutant gliomas differ fundamentally from IDH-wildtype gliomas in terms of metabolism, epigenetics, biological behavior, aggressive infiltration, vulnerable population, and response to therapy (9–12). The gene discussed is IDH2; the disease is central nervous system cancer.